Sub-Total: $0.00
Endocrinology
Showing all 9 results
-
New Horizons in Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes with SGLT-2, GLP-1 RAs and DPP-4 Based Therapies
Read more -
Changing Landscape of GLP-1 Receptor Agonists on Glycemic Control, Weight Reduction and Cardiovascular Outcomes in Individuals with Diabetes
Read more -
New Era in the Lipid Lowering Treatment with PCSK9 Inhibitors (Evolocumab and Alirocumab) in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia
Read more -
Efficacy and Safety of Fixed-ratio Combination of Insulin Degludec and Liraglutide (IDegLira) and Insulin Glargine and Lixisenatide (IGlarLixi) in Patients with Type 2 Diabetes
Read more -
Emerging Strategies in the Management of Dyslipidemia in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia: PCSK9 Inhibitors (Evolocumab and Alirocumab)
Read more -
Changing Landscape of Biological Therapies for Psoriasis: Promising Efficacy of Interleukin-17 (IL-17) and IL-2 Pathway Inhibitors
Read more -
Advances in GLP-1 Receptor Agonists, Insulins and SGLT-2 Inhibitors in the Treatment of Diabetes
Read more -
Individualized Treatment Options for Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists on Glycemic Control, Weight Reduction and Cardiovascular Risk
Read more -
Update on GLP-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus
Read more
